We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi/Luminostics to Make Self-Testing Solution for Coronavirus
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced that it has signed an agreement with Luminostics, a California-based technology startup for developing a smartphone-based self-testing solution that can detect the coronavirus. The testing solution will be based on Luminostics’ proprietary technology for consumer-diagnostics, while Sanofi will bring its research testing abilities and leverage its global distribution network to ensure global availability of the test, if approved. The self-testing solution will help individuals know in less than 30 minutes whether they are infected with this deadly virus.
While presently, point-of-care tests are available, Sanofi’s over-the-counter self-testing solution, if approved, will allow mass testing, which is the need of the hour for successful containment of the pandemic. The companies expect to begin development work in a few days and target to have the self-testing solution, if successfully developed, to be launched before the end of the year.
So far this year, Sanofi’s shares have declined 8.1% compared with the industry’s 4.6% decline.
Sanofi has announced several plans to make therapies/vaccines for treating COVID-19. Earlier this week, Sanofi and Glaxo (GSK - Free Report) signed a letter of intent to combine their innovative technologies to develop an adjuvanted COVID-19 vaccine. The vaccine candidate is expected to enter clinical studies in the second half of 2020. The vaccine, if successfully developed, will be available in the second half of 2021.
To make the vaccine, Sanofi will contribute the S-protein COVID-19 antigen developed using its recombinant DNA technology, which has helped produce an exact genetic match to proteins found on the surface of the virus.
Meanwhile, Glaxo will provide its proven pandemic adjuvant technology for the development of the coronavirus vaccine candidate. This technology may reduce the amount of vaccine protein required per dose, which, in turn, will allow more vaccine doses to be produced.
Sanofi also has a collaboration with Translate Bio (TBIO - Free Report) to jointly develop a novel messenger RNA (mRNA) vaccine for COVID-19.
Sanofi and partner Regeneron (REGN - Free Report) have started phase II/III studies both in and outside the United States to evaluate their rheumatoid arthritis drug, Kevzara for severe COVID-19 infection. While Regeneron is leading the U.S. studies, Sanofi is taking care of the ex-U.S. studies.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Sanofi/Luminostics to Make Self-Testing Solution for Coronavirus
Sanofi (SNY - Free Report) announced that it has signed an agreement with Luminostics, a California-based technology startup for developing a smartphone-based self-testing solution that can detect the coronavirus. The testing solution will be based on Luminostics’ proprietary technology for consumer-diagnostics, while Sanofi will bring its research testing abilities and leverage its global distribution network to ensure global availability of the test, if approved. The self-testing solution will help individuals know in less than 30 minutes whether they are infected with this deadly virus.
While presently, point-of-care tests are available, Sanofi’s over-the-counter self-testing solution, if approved, will allow mass testing, which is the need of the hour for successful containment of the pandemic. The companies expect to begin development work in a few days and target to have the self-testing solution, if successfully developed, to be launched before the end of the year.
So far this year, Sanofi’s shares have declined 8.1% compared with the industry’s 4.6% decline.
Sanofi has announced several plans to make therapies/vaccines for treating COVID-19. Earlier this week, Sanofi and Glaxo (GSK - Free Report) signed a letter of intent to combine their innovative technologies to develop an adjuvanted COVID-19 vaccine. The vaccine candidate is expected to enter clinical studies in the second half of 2020. The vaccine, if successfully developed, will be available in the second half of 2021.
To make the vaccine, Sanofi will contribute the S-protein COVID-19 antigen developed using its recombinant DNA technology, which has helped produce an exact genetic match to proteins found on the surface of the virus.
Meanwhile, Glaxo will provide its proven pandemic adjuvant technology for the development of the coronavirus vaccine candidate. This technology may reduce the amount of vaccine protein required per dose, which, in turn, will allow more vaccine doses to be produced.
Sanofi also has a collaboration with Translate Bio (TBIO - Free Report) to jointly develop a novel messenger RNA (mRNA) vaccine for COVID-19.
Sanofi and partner Regeneron (REGN - Free Report) have started phase II/III studies both in and outside the United States to evaluate their rheumatoid arthritis drug, Kevzara for severe COVID-19 infection. While Regeneron is leading the U.S. studies, Sanofi is taking care of the ex-U.S. studies.
Sanofi currently has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>